$5.67
6.38% day before yesterday
Nasdaq, Nov 14, 10:04 pm CET
ISIN
US90466Y1038
Symbol
UNCY

Unicycive Therapeutics Inc Stock price

$5.67
+1.11 24.34% 1M
+0.09 1.56% 6M
-2.27 28.61% YTD
+1.19 26.56% 1Y
-1.08 16.00% 3Y
-52.83 90.31% 5Y
-52.83 90.31% 10Y
-52.83 90.31% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
+0.34 6.38%
ISIN
US90466Y1038
Symbol
UNCY
Industry

Key metrics

Basic
Market capitalization
$121.9m
Enterprise Value
$99.5m
Net debt
positive
Cash
$22.3m
Shares outstanding
14.1m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 120.3
EV/Sales
- | 98.3
EV/FCF
negative
P/B
7.4
Financial Health
Equity Ratio
23.5%
Return on Equity
-509.0%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $1.0m
EBITDA
- | $-42.4m
EBIT
- | $-32.6m
Net Income
- | $-22.9m
Free Cash Flow
$-33.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -32.2%
EBIT
- | -1.4%
Net Income
- | 39.4%
Free Cash Flow
-53.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -4,188.8%
EBIT
-
Net
- | -2,262.5%
Free Cash Flow
-
More
EPS
-
FCF per Share
$-2.4
Short interest
7.1%
Employees
23
Rev per Employee
$0.0
Show more

Is Unicycive Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Unicycive Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Unicycive Therapeutics Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Unicycive Therapeutics Inc forecast:

Buy
93%
Hold
7%

Financial data from Unicycive Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
41% 41%
-
- Research and Development Expense 20 20
55% 55%
-
-32 -32
55% 55%
-
- Depreciation and Amortization 0.02 0.02
100% 100%
-
EBIT (Operating Income) EBIT -32 -32
55% 55%
-
Net Profit -38 -38
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Unicycive Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Unicycive Therapeutics Inc Stock News

Neutral
GlobeNewsWire
4 days ago
-   Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end -   Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden in terms of both pill volume (7x) and pill count (2x) compared to currently available phosphate binders -   Ended Q3 with $42.7 million of cash with...
Neutral
GlobeNewsWire
13 days ago
LOS ALTOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Monday...
Neutral
GlobeNewsWire
16 days ago
Defendants allegedly overstated Unicycive's FDA readiness for its OLC NDA; later cGMP issues at a subcontractor led to FDA setbacks and stock drops.
More Unicycive Therapeutics Inc News

Company Profile

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Head office United States
CEO Shalabh Gupta
Employees 23
Founded 2016
Website unicycive.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today